We are live on ! Find out more
TRDA icon

Entrada Therapeutics
TRDA

46 hedge funds and large institutions have $434M invested in Entrada Therapeutics in 2021 Q4 according to their latest regulatory filings, with 46 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

81.29% more ownership

Funds ownership: 0% → 81.29% (+81%)

Holders
46
Holders Change
+46
Holders Change %
–
% of All Funds
0.71%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.06%
New
46
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BBA
Baker Bros. Advisors
New York
+$114M
2
MAM
MPM Asset Management
Massachusetts
+$107M
3
5VM
5AM Venture Management
California
+$107M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$75.5M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$49M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
N
26
Nuveen
North Carolina
$237K +$336K +13,872 New
Bank of New York Mellon
27
Bank of New York Mellon
New York
$234K +$331K +13,657 New
Renaissance Technologies
28
Renaissance Technologies
New York
$232K +$329K +13,573 New
CSS
29
Cubist Systematic Strategies
Connecticut
$190K +$269K +11,090 New
CCM
30
CAAS Capital Management
New York
$171K +$243K +10,000 New
Deutsche Bank
31
Deutsche Bank
Germany
$95K +$135K +5,567 New
Wells Fargo
32
Wells Fargo
California
$91K +$129K +5,320 New
California State Teachers Retirement System (CalSTRS)
33
California State Teachers Retirement System (CalSTRS)
California
$86K +$122K +5,016 New
AIG
34
American International Group
New York
$83K +$118K +4,867 New
Morgan Stanley
35
Morgan Stanley
New York
$71K +$101K +4,162 New
JP Morgan Chase
36
JP Morgan Chase
New York
$60K +$84.7K +3,494 New
UBS Group
37
UBS Group
Switzerland
$48K +$68.2K +2,814 New
TRCT
38
Tower Research Capital (TRC)
New York
$42K +$60.1K +2,478 New
Citigroup
39
Citigroup
New York
$41K +$58K +2,393 New
SO
40
STRS Ohio
Ohio
$35K +$50.9K +2,100 New
Royal Bank of Canada
41
Royal Bank of Canada
Ontario, Canada
$32K +$45.2K +1,863 New
Legal & General Group
42
Legal & General Group
United Kingdom
$15K +$20.6K +848 New
AIP
43
Ameritas Investment Partners
Nebraska
$12K +$17.2K +708 New
Osaic Holdings
44
Osaic Holdings
Arizona
$5K +$7.28K +300 New
PHK
45
Point72 Hong Kong
Hong Kong
$4K +$5.21K +215 New
SOW
46
State of Wyoming
Wyoming
$4K +$5.6K +231 New
1
2

TRDA Hedge Fund Activity: Q4 2021 in Review

46 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q4 2021, worth a combined $434M.

Buyers outnumbered sellers: 46 funds opened new TRDA positions and 0 closed out — a net gain of 46 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $114M.

  • 46 institutional investors held Entrada Therapeutics (TRDA) as of Q4 2021, up from 0 in Q3 2021.
  • Funds reported $434M of Entrada Therapeutics stock for Q4 2021.
  • 46 funds opened new Entrada Therapeutics positions in Q4 2021 and 0 closed out, a net change of +46 holders.
  • The largest Entrada Therapeutics buyer in Q4 2021 was Baker Bros. Advisors, an estimated $114M added.

Based on aggregated 13F filings for Q4 2021.